Clinical trials: Complication of Hemodialysis
Renal Failure
Music Interventions for Patients Undergoing Hemodialysis
Fatigue is found to be one of the most persistent problems among patients in treatment with hemodialysis, and associated with impaired health-related quality of life.
- Trial name
- NCT04959682
- Testing
- Music Intervention
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Southern Denmark
Chronic Kidney Disease, Secondary Hyperparathyroidism
Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous
The purpose of this study is to assess health-related Quality of Life (QoL) changes in participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT) undergoing hemodialysis and receiving paricalcitol…
- Trial name
- QUALITIZE (NCT01368042)
- Where
- 11 sites in Greece
- Volunteers
- 265 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
End Stage Renal Disease
Impact of Clinical Pharmacy Services on Medication Cost and Hospitalization Rates in Hemodialysis Patients
The purpose of this study is to evaluate the effects of pharmaceutical care interventions in the ambulatory hemodialysis patients over a one-year period.
- Trial name
- NCT05952388
- Testing
- Behavioral Patient care
- Sponsor
- University of New Mexico
Healthy
Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension
To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with varying degrees of renal impairment
- Trial name
- NCT00637403
- Testing
- Megestrol acetate concentrated suspension 125 mg/mL
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Chronic Kidney Disease (CKD), Hyperkalemia
Chronic Kidney Disease, Hyperkalemia and Echocardiographic Changes
Patients with CKD ( eGFR \< \<60 mL/min/1,73 m2) presenting to emergency department with isolated hyperkalemia will be study population. Pre and post treatment ECG and echocardiographic findings will be recorded.
- Conditions
- Chronic Kidney Disease (CKD), Hyperkalemia, Hemodialysis
- Trial name
- NCT06635590
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Saglik Bilimleri Universitesi
End Stage Renal Disease
Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence
Patients in renal failure on hemodialysis depend on adequate and sustained vascular access. This can be achieved by surgical placement of a synthetic polytetrafluoroethylene (PTFE) graft.
- Trial name
- AdV-VANTAGE (NCT00895479)
- Testing
- Graft placement surgery plus Trinam therapy
- Where
- 12 sites in United States
- Volunteers
- 250 people
- Sponsor
- Ark Therapeutics Ltd
Hemodialysis Complication
Alpha Lipoic Acid Against Cardiovascular Events in Patients With Haemodialysis
Evaluate the association between possible benefit effects of oral administration of alpha lipoic acid by patients with hemodialysis and the possible reduction in cardiovascular events (CVEs); using Advanced glycation end products…
- Trial name
- NCT03912727
- Testing
- Alpha-Lipoic acid plus renal replacement therapy, renal replacement therapy
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Rehab Werida
Chronic Kidney Diseases, Hemodialysis Complication
Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients
After the end of trial, we will examine if cholestyramine has a significant efficacy on reducing serum phosphate level in adult hemodialysis patients.
- Conditions
- Chronic Kidney Diseases, Hemodialysis Complication, Hyperphosphatemia
- Trial name
- NCT05577507
- Testing
- Cholestyramine Resin 4000 MG [Questran], Calcium Carbonate 500 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
End Stage Renal Disease, Pruritus
Evaluating the Effect of Senna in Uremic Pruritus
Uremic pruritus remains one of the most frustrating and potentially disabling symptoms in patients with end stage renal disease. It affect up to 90 percent of patients with end stage renal disease.
- Trial name
- NCT02008864
- Testing
- Senna
- Volunteers
- 60 people
- Sponsor
- Shiraz University of Medical Sciences
Uremic Pruritus, Chronic Kidney Disease-associated Pruritus
Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis
Several studies investigated the effectiveness of Gabapentin in Uremic Pruritus (UP). No previous studies investigated the use of fexofenadine in UP.
- Conditions
- Uremic Pruritus, Chronic Kidney Disease-associated Pruritus, Hemodialysis, End-stage Renal Disease
- Trial name
- NCT06466421
- Testing
- Fexofenadine, Gabapentin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Kidney Failure, Chronic
Effect of Exercise on Endothelial Function and Vascular Compliance in Chronic Kidney Disease
The study hypothesis is that 6 weeks of repetitive handgrip exercise will improve endothelial function and venous compliance in pre-dialysis patients with an estimated glomerular filtration rate of less than or equal to 20…
- Trial name
- NCT01068314
- Testing
- Repetitive arm exercise
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Iowa
End Stage Kidney Disease
The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients
The purpose of this study is to explore the impact of an intradialytic exercise program on functional capacity, aerobic capacity, strength, quality of life, depression, hospitalizations and intradialytic episodes of hypotension.
- Trial name
- NCT01877863
- Testing
- exercise
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Hemodialysis Complication, Heart Failure
A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure
Chronic Kidney Disease often requires dialysis and other treatments to sustain life, and patients frequently suffer from heart failure, which exacerbates the disease burden.
- Trial name
- ESVGR-HF (NCT07047547)
- Testing
- Vericiguat
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Guangdong Provincial People's Hospital
End-stage Renal Disease (ESRD)
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
Evaluation of safety, tolerability, PK and PD of ISIS 416858 in patients with end-stage renal disease (ESRD) receiving chronic hemodialysis.
- Trial name
- NCT02553889
- Testing
- ISIS 416858
- Where
- 8 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Chronic Kidney Disease
Dialysis Clinical Outcomes Revisited (DCOR) Trial
This is a randomized, open-label, parallel-design study to be conducted at 75 centers within the United States. The study will be described to hemodialysis patients.
- Trial name
- NCT00324571
- Testing
- Sevelamer hydrochloride, Calcium-based phosphate binder
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Peritoneal Dialysis Complication, Hemodialysis Complication
The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
Patients with end stage renal disease (ESRD), especially after having maintenance dialysis are among the highest risk of heart failure (HF), which is the most important cause that affects survival rate and quality of life.
- Conditions
- Peritoneal Dialysis Complication, Hemodialysis Complication, Heart Failure
- Trial name
- NCT04572724
- Testing
- Sacubitril / Valsartan Oral Tablet, RAS Inhibitors
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Second People's Hospital
Kidney Diseases, End-Stage Kidney Disease
Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag)
Many patients on hemodialysis have low levels of magnesium. Magnesium is needed to keep the heart, kidneys, and other organs working properly.
- Conditions
- Kidney Diseases, End-Stage Kidney Disease, Hemodialysis
- Trial name
- NCT04079582
- Testing
- Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L)., Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).
- Where
- Canada
- Volunteers
- 25,000 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Coronary Artery Disease, End Stage Renal Disease
Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil
Nicorandil is potentially effective to prevent cardiovascular events in patients with coronary artery disease (CAD) receiving hemodialysis.
- Trial name
- NCT01475123
- Testing
- Nicorandil
- Where
- Japan
- Volunteers
- 268 people
- Sponsor
- Kumamoto University
Renal Insufficiency, Kidney Diseases
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
- Trial name
- NCT05624723
- Testing
- INCB054707
- Where
- 2 sites in United States, Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Renal Failure Chronic, Anemia
Predictors of Response to Iron and Erythropoietin Stimulating Agents
The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment.
- Trial name
- PRIME (NCT03658876)
- Testing
- Iron Sucrose Solution for Injection, Epoetin Beta
- Volunteers
- 197 people
- Sponsor
- Imperial College London